ASSET OVERVIEW
A closer look at the opportunity.
Promising Clinical Efficacy
50% ORR in SCLC, including 1 CR; 10/24 patients with >30% tumor shrinkage; PRs observed at 4 & 6 mg/kg dose groups.
Favorable Safety Profile
Most treatment-related adverse events (TRAE) were Grade 1 or 2, per CTCAE v5.0; No unexpected toxicities observed.
Best-in-Class Potential
B7-H3 overexpressed in multiple solid tumors (SCLC, NSCLC, prostate, HNSCC, esophagus, sarcoma).
Differentiated Design
Site-specific conjugation (DAR 6), Fc-silenced, potent TOPO-1 inhibitor (JS-1), bystander effect linker.
Next-Gen Molecular Design
Novel TOPO-1 inhibitor payload (JS-1) with higher potency than DXd. Linker is connected to the free sulfhydryls of reduced interchain disulfide bonds.
Preclinical Advantages
Outperforms DS-7300a in vitro & in vivo (LUAD, LUSC, EC). Strong dose-dependent tumor regression across CDX models.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities